Farideh Bischoff, PhD
- Health in Focus
- Women's Health in Focus 2025
Dr. Bischoff is an experienced professional with over 25 years of expertise in developing non-invasive clinical assays for various women’s health conditions such as endometriosis, IVF/ART, prenatal testing, and oncology. She has managed several research projects, published over 300 articles, and mentored executives and medical students alike. Dr. Bischoff has been recognized with numerous awards for her research, including the discovery of germline mutations in the p53 tumor suppressor gene.
As CEO and CSO of FreMon Scientific, she successfully led the company’s first commercial product, ZipThaw202, through FDA clearance and transitioned it to the commercial stage during the COVID-19 pandemic.
Dr. Bischoff has a Ph.D. in Cancer Biology and has received postdoctoral training from M.D. Anderson Cancer Center and Baylor College of Medicine.
Join the conversation at the next Health in Focus summit.
See the 2027 agendaBook a discovery call.
Tell us about your organisation and what you have in mind. We'll scope the right programme for your business, insurance book or workforce.